Background: A decision to stop or continue anticoagulation after 3 months of anticoagulation for venous thromboembolism (VTE) should be made by weighing individual risks of recurrence and bleeding.
Objectives: To determine the optimal ratio of recurrence risk reduction to increase the risk of bleeding in terms of maximizing quality-adjusted life years (QALYs) gained.
Methods: Using a microsimulation model, outcomes within 5 years were simulated after assigning extended treatment if absolute recurrence risk reduction outweighed absolute increase in clinically relevant bleeding risk (International Society on Thrombosis and Haemostasis definition), weighted by a certain ratio. Data were simulated based on the Bleeding Risk Study, a prospective cohort including patients after ≥3 months of anticoagulation for unprovoked VTE or provoked VTE with history of VTE. The VTE-PREDICT risk score was used to estimate 5-year risks of recurrent VTE and clinically relevant bleeding.
Results: Among 10,000 individuals (mean age, 60.2 years, 36% female), the ratio of 0.90 (95% CI, 0.51-3.40; ie, bleeding is considered 0.90 the severity of recurrent VTE), with 99% of patients assigned extended anticoagulation, was considered optimal and resulted in 93 (95% CI, -23 to 203) additional QALYs compared with the least favorable ratio (5.10, 0% extended anticoagulation). At the optimal ratio, treatment based on VTE-PREDICT yielded 44 (95% CI, -69 to 157) additional QALYs versus standard of care.
Conclusion: With the current evidence, the optimal ratio between relevant bleeding risk and absolute recurrence risk reduction remains uncertain. Our results confirm that clinical equipoise exists regarding the decision to stop or continue anticoagulation after initial VTE treatment, emphasizing the importance of shared decision-making.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784302 | PMC |
| http://dx.doi.org/10.1016/j.rpth.2023.102274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cancer-associated thrombosis: what is new?
Curr Opin Oncol
January 2025
Paris Cité University, Assistance-Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Interne, Hôpital Louis-Mourier, Inserm, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France.
Purpose Of Review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.
View Article and Find Full Text PDFDevelopment of Hollow Fiber Membranes Suitable for Outside-In Filtration of Human Blood Plasma.
Membranes (Basel)
January 2025
Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Zuidhorst 28, Drienerlolaan 5, 7522 NB Enschede, The Netherlands.
Hemodialysis (HD) is a critical treatment for patients with end-stage kidney disease (ESKD). The effectiveness of conventional dialyzers used there could be compromised during extended use due to limited blood compatibility of synthetic polymeric membranes and sub-optimal dialyzer design. In fact, blood flow in the hollow fiber (HF) membrane could trigger inflammatory responses and thrombus formation, leading to reduced filtration efficiency and limiting therapy duration, a consequence of flowing the patients' blood through the lumen of each fiber while the dialysate passes along the inter-fiber space (IOF, inside-out filtration).
View Article and Find Full Text PDFManagement of patients with venous thromboembolism and a high recurrence risk estimated by the Vienna Prediction Model: a prospective cohort study.
Res Pract Thromb Haemost
January 2025
Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Background: The Vienna Prediction Model (VPM) identifies patients with a first unprovoked deep vein thrombosis of the leg and/or pulmonary embolism who have a low recurrence risk and may, therefore, not benefit from extended-phase anticoagulation.
Objectives: The aim of this study was to evaluate patients with a predicted high risk of recurrent venous thromboembolism (VTE).
Methods And Results: We prospectively followed 266 patients in whom the VPM had predicted a recurrence risk of more than 5.
Improving Atrial Fibrillation or Flutter Detection and Management by Smartphone-Based Photoplethysmography Rhythm Monitoring Following Cardiac Surgery: A Pragmatic Randomized Trial.
Europace
January 2025
Department of Cardiovascular Sciences, UZ Leuven, Leuven, Belgium.
Background And Aims: Atrial fibrillation (AF) or atrial flutter (AFL) after cardiac surgery are common and associated with adverse outcomes. The increased risk related to AF or AFL may extend beyond discharge. This study aims to determine whether photoplethysmography (PPG)-based smartphone monitoring to detect AF or AFL after hospital discharge following cardiac surgery improves AF management.
View Article and Find Full Text PDFTreatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!